Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06403761
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2024-05-03
Brief Title:
Investigating How CagriSema Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Effect of CagriSema Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 Diabetes
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will look at how CagriSema semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes T2D CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide Doctors may not yet prescribe CagriSema Participants will either get CagriSema semaglutide cagrilintide or a dummy medicine Which treatment the participants will get is decided by chance Participants will get the study medicine together with the current daily diabetes medicine metformin Participants should not take other medicines for diabetes during the study The study will last for about 42 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1300-1930 | OTHER | None | None |
| 2023-509483-20 | OTHER | European Medical Agency EMA | None |